ArticleJournal of gynecologic oncology2026
Annual hazard rates for early-stage endometrial carcinoma after postoperative radiotherapy under FIGO 2023 staging system: results from a population-based single-center cohort study.
Article in Journal of gynecologic oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectiveTo investigate whether early-stage endometrial carcinoma (EC) patients have survival outcomes comparable to those of the general population, and further explore the dynamic recurrence/death surveillance value of International Federation of Gynecology and Obstetrics(FIGO) 2023 staging system.
methodsThis retrospective study analyzed FIGO 2009 stage I-II patients receiving postoperative radiotherapy at Peking Union Medical College Hospital in China (2000-2020), re-staged per FIGO 2023 staging system. Overall survival (OS) and disease-free survival (DFS) were assessed using Kaplan-Meier methods; mortality was compared to age-/sex-matched Chinese controls using standardized mortality ratios (SMRs); recurrence/death trajectories were modeled through annual hazard rates; FIGO 2023 recurrence prediction accuracy was assessed via receiver operating characteristics analysis.
resultsThis study of 1222 EC patients revealed upstaging from FIGO 2009 to 2023 (IA→II: 27.2%; IB→II: 26.4%). OS rates were 97.7% (3-year), 94.9% (5-year), and 91.0% (10-year), with corresponding DFS rates of 93.4%, 87.4%, and 82.8%. Under FIGO 2023 staging system, recurrence risk peaked at 1.3 years (3.5%) and declined after 3 years. Mortality risk increased within 4 years, stabilizing at about 1.0% thereafter. IC/IIC stages showed the earliest/highest risk peaks. Stage IA1-IA2 required monitoring for late recurrences (>3 years), while IIC needed vigilance for delayed mortality (>3 years). FIGO 2023 staging system was an independent prognostic factor for recurrence prediction (area under the curve: 1-year=0.644; 3-year=0.612; 5-year=0.611).
conclusionEarly-stage EC patients had favorable prognosis. FIGO 2023 staging system exhibit excellent recurrence surveillance and prognostic prediction for these patients after postoperative radiotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.